Glioblastoma multiforme small molecule
Total Trials
2
As Lead Sponsor
1
As Collaborator
Total Enrollment
108
NCT05053880
A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme
Phase: Phase 1/2
Role: Lead Sponsor
Start: Sep 22, 2021
Completion: Nov 30, 2023
NCT06838676
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
Phase: Phase 2
Role: Collaborator
Start: Jul 10, 2025
Completion: Jul 31, 2035
Loading map...